CellCentric, a cutting-edge biotechnology company in cancer therapy, is pleased to announce the successful raise of a $120 million Series C round. The significant investment will be used to further drive the development of its top candidate drug, inobrodib, an oral p300/CBP inhibitor for individuals suffering from multiple myeloma.
Phase II, a dose-optimisation clinical trial, is currently underway with an all-oral triplet of inobrodib, pomalidomide, and dexamethasone.
The financing round was co-led by lead life science investors RA Capital Management and Forbion. Additionally, Avego Bioscience Capital and BrightEdge, the venture capital and impact investment subsidiary of the American Cancer Society, participated.
The freshly raised funds will be instrumental in moving Inobrodib into later-stage clinical development. One of the top priorities is to start a Phase II/III trial in heavily pretreated multiple myeloma patients, which is a subgroup with high unmet medical needs. The company believes that the outcome of this trial could support the opportunity to file for an accelerated approval for inobrodib.
In addition, the investment will fund more extensive development initiatives, such as planning for a Phase III program that is projected to start in mid-2026. CellCentric will also seek the therapeutic value of inobrodib in combination regimens. Clinical trials will start in the second quarter of 2025 to test inobrodib with bi-specific antibodies and as maintenance therapy, to increase its potential impact on multiple myeloma management.
Inobrodib
Inobrodib is an emerging cancer treatment, specifically for multiple myeloma. It is a small-molecule therapy that acts on p300/CBP, reducing the expression of MYC and IRF4, the most critical cancer drivers. Given orally as a capsule, it is convenient for patients to self-administer and use at home without extensive monitoring. Since it is safe and has a good profile for a drug in this context, it can be utilized by individuals who cannot access or endure other forms of treatment. It can potentially offer a lower overall burden to the healthcare system compared to more complicated agents.
Last Modified:
